Results for this period
Third quarter1 January 2026 to 30 September 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In Japan, although the business was affected by drug price revisions and the penetration of generic drugs, sales of core and new products increased, and shipment dates for pharmaceutical wholesalers were brought forward as part of the transition preparations for the ERP go-live. Overseas, exports of NEMLUVIO to Galderma and Alecensa to Roche increased. Royalty income and one-time payment income also rose.
None.
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026 to 30 September 2026 |
| Net Sales | ¥1,068,074 million (YoY +17.2%) |
| Operating profit | ¥522,570 million (YoY +21.6%) |
| Ordinary income | ¥533,906 million |
| Profit attributable to owners of the parent | ¥375,302 million (YoY +22.8%) |
| Net income per share | ¥228.07 |
| Equity ratio | End of the current fiscal period 88 / End of previous period 82.1 |
| Total assets | ¥2,374,320 million |
| Net assets | ¥2,088,536 million |
| Cash flows from operating activities | ¥306,325 million |
| Cash flows from investing activities | ¥13,579 million |
| Cash flows from financing activities | ¥-361,789 million |
| Cash and cash equivalents at end of period | ¥382,305 million |
| Full-year earnings forecast | Standard Core basis / Net Sales ¥1,345,000 million (YoY +6.9%) / Operating profit ¥670,000 million (YoY +7.5%) / Ordinary income Not disclosed / Net income ¥485,000 million (YoY +7.5%) |
| Annual Dividend Forecast | 272 yen → 132 yen（-51.5%） |
| Payout ratio | 44.7 |
| Regional sales | Region Japan / Sales of products and merchandise ¥406,344 million / Other revenue ¥502 million, Region Overseas expansion / Sales of products and merchandise ¥500,474 million / Other revenue ¥160,754 million, Region Of which: Switzerland / Sales of products and merchandise ¥475,603 million / Other revenue ¥137,535 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Item Business restructuring costs, etc. / Amount ¥116 100 million / Remarks Included in IFRS results and excluded on a Core basis |
| Disclosure regarding the going concern assumption | None. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Availability of Supplementary Financial Results Materials | Available |
| Availability of Financial Results Briefing | Whether applicable Available / Subject person Institutional investors, securities analysts and the media |
| Issued Shares at Period-End | 1,679,057,667 shares |
| Treasury Shares at Period-End | 33,755,014 shares |
| Factors Behind Changes in Business Performance | In Japan, although the business was affected by drug price revisions and the penetration of generic drugs, sales of core and new products increased, and shipment dates for pharmaceutical wholesalers were brought forward as part of the transition preparations for the ERP go-live. Overseas, exports of NEMLUVIO to Galderma and Alecensa to Roche increased. Royalty income and one-time payment income also rose. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales increased for core products including Polivy, Hemlibra and Vabysmo, as well as new products such as Lunsumio and Elevidys. Overseas, exports of NEMLUVIO to Galderma and Alecensa to Roche increased, while royalty income and one-time payment income also rose.